Accelerated Predictive Stability (APS) - 1st Edition - ISBN: 9780128027868

Accelerated Predictive Stability (APS)

1st Edition

Fundamentals and Pharmaceutical Industry Practices

Authors: Fenghe Qiu Garry Scrivens
Hardcover ISBN: 9780128027868
Imprint: Academic Press
Published Date: 1st June 2018
Page Count: 416
Tax/VAT will be calculated at check-out Price includes VAT (GST)

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Accelerated Predictive Stability (APS): Fundamentals and Pharmaceutical Industry Practices provides coverage of both the fundamental principles and pharmaceutical industry applications of the APS approach. APS is an innovative science and risk-based pharmaceutical stability testing approach that has become increasingly popular in recent years. The fundamental chapters authored by the most respected scientists in this field explain the scientific basis of the APS approach, while the case study chapters from many innovative pharmaceutical companies provide a thorough overview of the current status of APS applications in the pharmaceutical industry as well as numerous specific examples on where and how APS can be applied in the drug development life cycle. In addition, the up-to-date experiences in utilizing APS data for regulatory submissions in many regions and countries highlight the potential of APS in support of registration stability testing for certain regulatory submissions. This book provides high level strategies for a successful implementation of APS in a pharmaceutical company and sufficient details for newcomers to practice APS at the bench level. It offers scientists and regulators a comprehensive resource on how the pharmaceutical industry can enhance their understanding of a product’s stability and predict drug expiry more accurately and quickly.

Key Features

  • A comprehensive one-stop-shop resource for accelerated predictive stability (APS)
  • Scientific basis of different APS models explained
  • Applications and utilities of APS demonstrated through numerous case studies
  • Up-to-date regulatory experience included

Readership

Scientists/managers in drug development, pharmaceutical scientists, analytical chemists, regulatory affairs officials, quality assurance and quality control professionals, professionals in regulatory agencies and pharmaceutical science graduate students

Table of Contents

Part I: General Chapters
1. Introduction
2. Regulatory Expectations and Industry Practice on Stability Testing
3. ASAP Theory and Fundamentals
4. Practical Considerations
5. Packaged Products
6. Data Evaluation and Statistical Methods
7. Assessing the Suitability of ASAP for the Sample
8. Application of ASAP in the Pharmaceutical Industry
9. The Value of ASAP in Early Clinical Drug Product Development
10. Embedding ASAP within Business
11. ASAP Regulatory Strategy and Acceptance and Feedback

Part II: Industry Practices
12. ASAP Application in Product Development
13. Methods for the Analysis of Data from Accelerated Stability Studies
14. ASAP Application in Packaging Selection
15. ASAP Application in Post-approval Process Development
16. Using ASAP to Predict the Retest Period of an Unusually Unstable Drug Substance and to Select Prototype Formulations
17. Shelf Life Prediction and Packaging Selection of a Humidity-sensitive Product
18. ASAP Application in Suspension and Lyophilized Products
19. ASAP Application in Generic Products
20. Application of ASAP to Nicrette® Lozenges
21. Implementing an Accelerated Stability Assessment Program
22. ASAP: Case Studies from Early and Late Pharmaceutical Development Stages
23. Application of ASAP for Dissolution Predictions

Details

No. of pages:
416
Language:
English
Copyright:
© Academic Press 2018
Published:
Imprint:
Academic Press
Hardcover ISBN:
9780128027868

About the Author

Fenghe Qiu

Dr. Fenghe Qiu has over 30 years of combined academic and industry experiences as an analytical scientist and published over 50 peer reviewed articles and gave over 25 invited presentations. He received his Ph.D. in Physical Chemistry from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences and a B.S. degree in Chemistry from Shandong University. He has been with Boehringer Ingelheim Pharmaceuticals Inc. for over 16 years and currently is a Senior Research Fellow in the Department of Material and Analytical Sciences. In his current role, Dr. Qiu is responsible for analytical development of new chemical entity (NCE) small molecule drugs and provides leadership role in many CMC development areas such as project management, method development/validation, elucidation of structure, impurity/mutagenic impurity control, stability/stress testing, specification, quality control, and regulatory submissions. He has led many internal innovation initiatives in areas including mutagenic impurity, stress testing, accelerated predictive stability (APS) and emerging technologies, etc. He is the inventor of the BI Mutagenic Impurity Workspace, the current organizer of the Mutagenic Impurity Advisory Council, the local process owner for stability and head of quality control. He also extensively involved in many industry initiatives under PhRMA, AAPS, USP and IQ, etc., and currently served in three IQ working groups involving accelerated predictive stability, lean stability and impurity metrics. Prior to BI, Dr. Qiu had several academic assignments including Mass Spectrometry Lab Manager, Northwestern University, Research Associate, University of Utah, and Associate Professor, National Center of Biomedical Analysis of China.

Affiliations and Expertise

Senior Research Fellow, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

Garry Scrivens

Garry Scrivens is a Senior Principal Scientist, Analytical R&D, Worldwide Pharmaceutical Sciences (WWPS), and is based in Sandwich, Kent. He is currently a group leader responsible for the late-stage development and filing of drug products. His Ph.D in physical organic chemistry, was a spectroscopic investigation into the mechanisms and kinetics of metal-catalyzed redox reactions. He has 15 years pharmaceutical analytical development experience, and has worked on numerous APIs and drug products, from inhaled to solid oral dosage forms. He has an interest in solid-state degradation chemistry and the accurate prediction of shelf life; he is a champion of the Accelerated Stability Assessment Program (ASAP) developed at Pfizer.

Affiliations and Expertise

Senior Principal Scientist, Pfizer Ltd, Sandwich, UK